
LENZ and Lotus Pharmaceutical collaborate to commercialise presbyopia treatment
US-based LENZ Therapeutics has announced an exclusive licensing and commercialisation agreement with Lotus Pharmaceutical of Taiwan for the commercialisation of the former’s LNZ100, a presbyopia treatment, in the Republic of Korea and select Southeast …